Dr Reddy’s Labs shares up 3% after Q2 results. What should investors do?

November 6, 2024

Dr. Reddy’s Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowledge the strong revenue momentum, opinions are divided on the stock’s future prospects, with ratings ranging from ‘Buy’ to ‘Sell’.

More To Explore

Azad Engineering block deal: Nomura picks stake worth Rs 66 crore in this smallcap defence stock

Nomura acquired over 4.1 lakh shares in Azad Engineering for Rs 66 crore through a block deal at an 8% discount. Despite the investment, Azad’s

June 7, 2025

Cochin Shipyard, Astrazeneca among top 10 small-cap gainers this week, rallying up to 28%

Indian stock benchmarks Sensex and Nifty recorded their first weekly gain this week after two straight weeks of decline. On the weekly front, the BSE

June 7, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003